Paragonix Technologies said today that the FDA granted 510(k) clearance for a design change to its SherpaPak heart transport device so that it can be used with small and pediatric hearts.
Braintree, Mass.-based Paragonix said it will begin shipping heart connectors covering most aortic diameters during the first quarter of 2019.
“This FDA clearance is an important milestone in making the Paragonix SherpaPak CTS accessible for all donor populations, increasing the market reach of this important transplant product,” chairman & CEO Bill Edelman said in prepared remarks. “Our goal is to establish a new standard of care for donor organ preservation and with our FDA cleared and CE marked devices for both heart and kidney organ stage and transport, we are on our way to make this a reality.”
Paragonix won won 510(k) clearance from the FDA in December 2014 for the SherpaPak heart device and landed CE Mark approval in the European Union in February.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.